Send them to me, business editor Michael McCoy, at m_mccoy@acs.org. The Indian chemical maker Deepak Nitrite is moving forward with plans to build a bisphenol A plant in Dahej, India. The plant will ...
Parabilis Medicines is rated a Buy; it leverages rare, genetically simple tumors to validate its Helicon platform. Read more ...
KNOXVILLE, Tenn.-- (BUSINESS WIRE)--Aug 14, 2026-- ...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
Seattle biotech InduPro has raised $77 million and dosed its first patient in a Phase 1 trial of an experimental cancer drug, ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset ...
R&D Expense: Research and development expenses for the second quarter of 2026 were $29.3 million, as compared to $38.7 million for the same period in 2025. The decrease was primarily due to a ...
A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a portion of Neurimmune’s royalty interest in ...
At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q2 2026 Investor Update Conference Call. [Operator Instructions] I would like to now turn the call over to Chris Stamm, ...
JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ...
Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today ...
Definium Therapeutics is a Strong Buy after positive phase 3 VOYAGE DT120 ODT GAD data. Click to read the latest analysis on the stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results